ArticlePolymers2023
Oligomerization Strategy of D-A-Type Conjugated Molecules for Improved NIR-II Fluorescence Imaging.
Article in Polymers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Fluorescence imaging (FI) in the second near-infrared (NIR-II) window has emerged as a promising imaging method for cancer diagnosis because of its superior properties such as deep penetration depth and high signal-to-background ratio. Despite the superiorities of organic conjugated nanomaterials for NIR-II FI, the issues of low fluorescence quantum yield, weak metabolic capability, undefined molecular structure for conjugated polymers, weak light-harvesting ability, short emission wavelength, and high synthetic complexity for conjugated small molecules still remain to be concerned. We herein propose an oligomerization strategy by facilely adjusting the oligomerization time to balance the advantages and disadvantages between conjugated polymers and small molecules, obtaining the candidate (CO1, oligomerization time: 1 min) with the optimal NIR-II optical performance. Then the CO1 is further prepared into water-dispersed nanoparticles (CON1) via a nanoprecipitation approach. By virtue of the suitable size, excellent NIR-II optical properties, low toxicity, and strong cell-labeling ability, the CON1 is successfully employed for in vivo NIR-II imaging, permitting the real-time visualization of blood vascular system and tumors with high sensitivity and resolution. This work thus not only provides a personalized organic conjugated nano-agent for NIR-II FI, but also highlights the molecular strategy for the development of organic conjugated systems with optimal performance for bio-imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.